65,437 trials
Complicated Urinary Tract Infection
Primary: Number of Participants With Microbiological Outcome at the Test of Cure (TOC) Visit — 19; 25 Participants
Hormone-refractory Prostate Cancer · Adenocarcinoma of the Prostate · Hormone-resistant Prostate Cancer
Primary: Number of Subjects With Disease Control (DC) (Based on PSA, Bone Scan, FACT-P, RECIST) — 5 Participants
Healthy
Primary: Change in Blood Oxygenation Level Dependent (BOLD) Activation in the Amygdala During "Win" Monetary Incentive Delay (MID) Task Between Placebo and Study Medication…
Pulmonary Artery Stenosis
Primary: Acute Change in Minimum Lumen Diameter Immediately Post-intervention — 85.1; 52.4 percentage change
Spinal Fusion Acquired · Spinal Stenosis · Lesions of Lumbosacral Intervertebral Disc
Primary: Time Required After Surgery to Reach Fitness for Discharge From Hospital — 3.2; 3.2 days — p=0.36
Acute Biphenotypic Leukemia · Acute Myeloid Leukemia · Myelodysplastic Syndrome
Primary: Treatment-related Mortality Rate. (TRM) — 6; 2 Participants
Musculoskeletal Pain · Chronic Pain
Primary: Change From Baseline in Pain-related Interference on the Patient Reported Outcomes Measurement Information System (PROMIS) Scale at 26 Weeks — -3.22; -1.85 units on a…
Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Primary: Recurrence-Free Survival — 58.1; 55.6 percentage of patients
Sleep Onset Insomnia
Primary: Sleep Onset Latency (Mins) — 13; 19 minutes — p=0.011
Moderate to Severe Chronic Plaque-Type Psoriasis
Primary: Long-term Safety and Tolerability of Secukinumab — 88.3; 92.0; 92.9; 78.2 Percentage of participants
Neurofibromatosis Type 1 · Sarcoma
Primary: Number of Participants With Response Rate (Complete Response and Partial Response) — 5; 4; 0; 0 Participants
Leukemia · Lymphoma · HIV
Primary: Percentage of Participants With Non-Relapse Mortality — 0.0; 11.8; 18.3 percentage of participants
Methamphetamine Dependence
Primary: Methamphetamine Days of Abstinence : Proportion of Days Abstinent — .56; .55; .74; .74 proportion of days abstinent — p=.47
Nicotine Dependence
Primary: End-of-treatment Abstinence — 25; 13 Participants — p=0.011
Food Hypersensitivity
Primary: Determine the Percentage of Subjects Who Demonstrate Sustained Unresponsiveness (SU) by a Negative Double-blind Placebo-controlled Food Challenge (DBPCFC). — 29…